PRS by case-control status and the association with CLL risk by FH status: InterLymph data
| . | Overall . | FH− . | FH+ . | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Controls (N = 2459) . | CLL (N = 1499) . | CLL vs controls . | Controls (N = 1626) . | CLL (N = 783) . | CLL vs controls . | Controls (N = 130) . | CLL (N = 112) . | CLL vs controls . | ||||||||||||
| PRS, range* . | N . | % . | N . | % . | OR† . | 95% CI . | P . | N . | % . | N . | % . | OR† . | 95% CI . | P . | N . | % . | N . | % . | OR† . | 95% CI . | P . |
| Q1 (4.32- 6.80) | 543 | 22.1 | 80 | 5.3 | .36 | 0.26-0.48 | 9.96 × 10−12 | 362 | 22.3 | 42 | 5.4 | 0.32 | 0.21-0.48 | 1.98 × 10−8 | 28 | 21.5 | 2 | 1.8 | 0.10 | 0.01-0.89 | .04 |
| Q2 (6.80- 7.32) | 491 | 20.0 | 152 | 10.1 | .73 | 0.56-0.94 | .016 | 322 | 19.8 | 73 | 9.3 | 0.67 | 0.47-0.95 | .023 | 26 | 20.0 | 11 | 9.8 | 1.12 | 0.34-3.69 | .86 |
| Q3 (7.32-7.77) | 477 | 19.4 | 218 | 14.6 | Ref | — | — | 318 | 19.6 | 113 | 14.4 | Ref | — | — | 26 | 20.0 | 11 | 9.8 | Ref | — | — |
| Q4 (7.77-8.28) | 466 | 19.0 | 315 | 21.0 | 1.65 | 1.31-2.08 | 1.9 × 10−5 | 303 | 18.6 | 181 | 23.1 | 1.65 | 1.22-2.23 | .001 | 23 | 17.7 | 24 | 21.4 | 2.79 | 0.94-8.26 | .06 |
| Q5 (8.28-11.31) | 482 | 19.6 | 733 | 48.9 | 3.64 | 2.94-4.51 | 1.07 × 10−32 | 321 | 19.7 | 374 | 47.8 | 3.29 | 2.49-4.35 | 6.98 × 10−17 | 27 | 20.8 | 64 | 57.1 | 7.58 | 2.74-21.0 | 9.8 × 10−5 |
| Continuous | 2.49 | 2.28-2.80 | 4.40 × 10−94 | 2.46 | 2.19-2.76 | 1.79 × 10−53 | 3.79 | 2.44-5.87 | 2.67 × 10−9 | ||||||||||||
| PRS (median) | 7.50 | 8.25 | 7.49 | 8.23 | 7.55 | 8.43 | |||||||||||||||
| c-statistics | 0.79 | 0.78-0.80 | 0.791 | 0.77-0.81 | 0.861 | 0.82-0.90 | |||||||||||||||
| . | Overall . | FH− . | FH+ . | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Controls (N = 2459) . | CLL (N = 1499) . | CLL vs controls . | Controls (N = 1626) . | CLL (N = 783) . | CLL vs controls . | Controls (N = 130) . | CLL (N = 112) . | CLL vs controls . | ||||||||||||
| PRS, range* . | N . | % . | N . | % . | OR† . | 95% CI . | P . | N . | % . | N . | % . | OR† . | 95% CI . | P . | N . | % . | N . | % . | OR† . | 95% CI . | P . |
| Q1 (4.32- 6.80) | 543 | 22.1 | 80 | 5.3 | .36 | 0.26-0.48 | 9.96 × 10−12 | 362 | 22.3 | 42 | 5.4 | 0.32 | 0.21-0.48 | 1.98 × 10−8 | 28 | 21.5 | 2 | 1.8 | 0.10 | 0.01-0.89 | .04 |
| Q2 (6.80- 7.32) | 491 | 20.0 | 152 | 10.1 | .73 | 0.56-0.94 | .016 | 322 | 19.8 | 73 | 9.3 | 0.67 | 0.47-0.95 | .023 | 26 | 20.0 | 11 | 9.8 | 1.12 | 0.34-3.69 | .86 |
| Q3 (7.32-7.77) | 477 | 19.4 | 218 | 14.6 | Ref | — | — | 318 | 19.6 | 113 | 14.4 | Ref | — | — | 26 | 20.0 | 11 | 9.8 | Ref | — | — |
| Q4 (7.77-8.28) | 466 | 19.0 | 315 | 21.0 | 1.65 | 1.31-2.08 | 1.9 × 10−5 | 303 | 18.6 | 181 | 23.1 | 1.65 | 1.22-2.23 | .001 | 23 | 17.7 | 24 | 21.4 | 2.79 | 0.94-8.26 | .06 |
| Q5 (8.28-11.31) | 482 | 19.6 | 733 | 48.9 | 3.64 | 2.94-4.51 | 1.07 × 10−32 | 321 | 19.7 | 374 | 47.8 | 3.29 | 2.49-4.35 | 6.98 × 10−17 | 27 | 20.8 | 64 | 57.1 | 7.58 | 2.74-21.0 | 9.8 × 10−5 |
| Continuous | 2.49 | 2.28-2.80 | 4.40 × 10−94 | 2.46 | 2.19-2.76 | 1.79 × 10−53 | 3.79 | 2.44-5.87 | 2.67 × 10−9 | ||||||||||||
| PRS (median) | 7.50 | 8.25 | 7.49 | 8.23 | 7.55 | 8.43 | |||||||||||||||
| c-statistics | 0.79 | 0.78-0.80 | 0.791 | 0.77-0.81 | 0.861 | 0.82-0.90 | |||||||||||||||